Journal of Carcinogenesis
Covering Genesis to Therapeutics
Journal of Carcinogenesis, ISSN: 1477-3163
2025; Vol 24: Issue 4s, https://carcinogenesis.com/

Assessing Liver Volume as a Prognostic Indicator in Cirrhosis

Roshni P.R [1]*, Kirti Theresa Alexander[1], Manu Raj[3], Shine Sadasivan[2]

[1*.]Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala-682041, India.

[1]Asst. Professor, Dept of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi,Kerala-682041, India .

[2]HOD, Professor, Dept of Gastroenterology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi,Kerala-682041, India.

[3]Professor, Department of Paediatrics, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi,Kerala-682041, India.

Corresponding author: Roshni P R, roshnipr@aims.amrita.edu

ABSTRACT

Cirrhosis presents significant obstacles in predicting patient outcomes, highlighting the need for reliable markers to guide clinical decisions. Liver volume, measured using advanced imaging methods such as computed tomography (CT) and magnetic resonance imaging (MRI), provides a structural assessment of liver function that goes beyond traditional blood tests. This review compiles evidence up to March 2025 on liver volume's role as a prognostic indicator in cirrhosis, exploring its relationships with mortality, hepatic decompensation, and results after procedures like transjugular intrahepatic portosystemic shunt (TIPS) or liver transplantation. Studies consistently show that liver volumes below 800-1000 cm^3 are associated with higher risks of death and complications, while the liver-to-spleen volume ratio (LSVR) offers an additional gauge of disease severity.

Despite its clear value, liver volume isn't yet a standard tool in practice due to varying measurement techniques and a lack of agreed-upon normal ranges. Pairing it with established systems like the Model for End-Stage Liver Disease (MELD) score could sharpen predictions and create a more comprehensive risk evaluation. This review examines how liver volume is measured, its practical implications, and the barriers to its broader use, while pointing to future research directions to boost its role in cirrhosis management. The data suggest that liver volume, as a direct measure of liver health, could complement existing tools, paving the way for earlier interventions and more tailored treatments. To fully realize its potential, though, standardized methods and thorough validation are essential.

Keywords: *Cirrhosis, Liver Volume, CT, MELD Score , TIPS , LSVR*

How to Cite: Roshni P.R, Kirti Theresa Alexander, Manu Raj, Shine Sadasivan, (2025) Assessing Liver Volume as a Prognostic Indicator in Cirrhosis, *Journal of Carcinogenesis, Vol.24, No.4s,* 794-809

1. INTRODUCTION

Cirrhosis develops from ongoing fibrosis and structural damage to the liver, leading to impaired function and the onset of portal hypertension. Accurate tools for predicting outcomes are critical for assessing risk and shaping treatment plans. Traditional measures like the Model for End-Stage Liver Disease (MELD) and Child-Pugh scores rely heavily on lab results and clinical symptoms to gauge disease severity. However, these approaches may not fully capture the liver's structural and functional decline. Liver volume, which reflects the amount of remaining liver tissue and its ability to regenerate, has gained attention as a potential marker. This review examines liver volume as a biomarker in cirrhosis, focusing on how it's measured and its links to patient outcomes.

Unlike MELD and Child-Pugh scores, which depend on blood tests and visible symptoms, liver volume offers a direct look at how much healthy liver is left and its capacity to recover. Research shows that smaller liver volumes—especially when adjusted for ideal body weight—are tied to worse outcomes, including higher death rates and a greater need for liver transplantation. This connection holds even when accounting for MELD scores, suggesting liver volume reveals aspects of

disease severity that standard tools might miss. Another key measure is the liver-to-spleen volume ratio (LV/SV), which shifts as cirrhosis advances. Early on, the liver may enlarge to compensate, but in later stages, it shrinks while the spleen grows due to portal hypertension. A low LV/SV ratio—specifically below 83.9%—has been linked to more complications and lower survival rates, especially in acute liver failure. This ratio proves useful for tracking disease progression and deciding when interventions like transplantation might be necessary. Adding liver volume and LV/SV to existing prognostic models could improve how we evaluate cirrhosis and customize patient care.

Table 1: Comparison of Prognostic Tools in Cirrhosis

Prognostic Tool	Parameters Used	Strengths	Limitations
MELD	Bilirubin, INR, Creatinine	Widely used, good for short-term mortality	Based on lab values which can fluctuate
Child-Pugh	Clinical symptoms, lab values	Assesses clinical severity	Subjective components
Liver Volume	Imaging (CT, MRI)	Direct structural assessment	Varying measurement techniques, lack of standardization

Comparison (Compares prognostic tools in cirrhosis). Model for End -Stage Liver Disease (MELD), International Normalized Ratio (INR), Computed Tomography (CT), Magnetic Resonance Imaging (MRI),

Recent strides in CT and MRI technology have made liver volume measurements more reliable. Scientists have also devised formulas to estimate a "standard" liver volume based on body size, allowing for more individualized assessments. Beyond that, research is digging into how factors like muscle loss (sarcopenia) and fat distribution might work alongside liver volume to affect outcomes. Looking forward, artificial intelligence (AI) and advanced imaging techniques could push liver volumetry to new heights. By integrating real-time volume data with lab results, genetic profiles, and other clinical indicators, we might soon predict disease paths with greater precision, paving the way for more tailored and effective management strategies with greater precision.[11] While more research is needed to standardize measurement techniques and validate cutoff values, liver volume is proving to be a powerful addition to the toolbox for managing cirrhosis—one that could lead to earlier interventions and better-tailored care for patients.

2. LIVER VOLUME MEASUREMENT TECHNIQUES

Accurate assessment of liver volume is essential as a prognostic marker in cirrhosis, a progressive disorder characterized by deteriorating hepatic function. This evaluation relies on advanced imaging technologies, with computed tomography (CT) and magnetic resonance imaging (MRI) being the most precise modalities. These methods generate high-resolution three-dimensional reconstructions, achieving a measurement accuracy of 3–5% relative to the actual anatomical volume [3]. Both techniques employ semi-automated or fully automated segmentation algorithms, minimizing inter-observer discrepancies and enhancing reproducibility compared to traditional manual approaches.

In contrast, ultrasonography offers a cost-effective and portable alternative, frequently used for point-of-care assessments. Nevertheless, its diagnostic reliability is limited by operator-dependent variability and reduced visualization in advanced cirrhosis, diminishing its consistency in volumetric analysis [4]. To account for physiological differences among individuals, liver volume is often standardized using parameters such as body weight or spleen volume, enabling more uniform comparisons across patient populations.

Table 2: Liver Volume Measurement Techniques

Technique	Pros	Cons	Accuracy
CT	High accuracy, reliable	Radiation exposure, segmentation pitfalls	3-5%
MRI	No radiation, high accuracy	Time-consuming, expensive	3-5%
Ultrasonography	Safe, inexpensive	Lower accuracy	Operator-dependent variability

T*echniques* (Liver volume measurement techniques). Computed Tomography (CT), Magnetic Resonance Imaging (MRI)

In healthy adults, the liver typically measures between 1400 and 1600 cm³, reflecting adequate functional parenchyma to sustain metabolic demands [3]. However, in cirrhosis, progressive fibrosis and loss of viable tissue result in significant volumetric reduction, often declining by 30–40% in advanced stages. This reduction strongly correlates with disease severity, reinforcing its clinical relevance [4].The choice of imaging modality depends on clinical objectives: CT and MRI are preferred for preoperative planning and detailed prognostic assessments due to their superior accuracy, whereas ultrasonography serves as a practical initial screening tool despite its inherent limitations [5]. Emerging advancements, including artificial intelligence-assisted segmentation, further refine measurement precision, reduce processing time, and improve consistency. These innovations underscore the growing feasibility of integrating liver volumetry into routine clinical practice, providing a quantitative measure of hepatic reserve that aids in therapeutic decision-making and patient management [6].



Diagram 1: Overview of Liver Volume Measurement Techniques

Table 3: Comparison of Techniques various techniques for liver volume assessment

Technique	Pros	Cons
Manual Volumetry	High accuracy	Time-consuming, labor-intensive
CT	High accuracy, reliable	Radiation exposure, segmentation pitfalls
MRI	No radiation, high accuracy	Time-consuming, expensive
Ultrasonography	Safe, inexpensive	Lower accuracy
3D Virtual Planning Software	Reduces time and effort	Requires high-quality imaging and software
Deep Learning Algorithms	High accuracy, efficiency, reproducibility	Requires large datasets
Photoshop-Based Method	Good correlation with actual volumes	Manual, time-consuming
Angulometry	Useful for surgical planning	Limited to volume ratios

Methods (Comparison of techniques for liver volume assessment). Computed Tomography (CT), Magnetic Resonance Imaging (MRI)

3. ADVANCED IMAGING TECHNIQUES FOR PRECISE LIVER VOLUME ASSESSMENT IN CIRRHOSIS MANAGEMENT

In modern hepatology, the precise measurement of liver volume plays a crucial role in the comprehensive clinical evaluation and management of cirrhosis. Recent advancements in medical imaging have substantially enhanced diagnostic capabilities, allowing for detailed and reliable hepatic morphological assessments. Computed tomography (CT) and magnetic resonance imaging (MRI) currently represent the gold-standard modalities, offering high-resolution cross-sectional visualization. These techniques employ advanced segmentation algorithms to facilitate precise volumetric

calculations. A key advantage of these imaging methods is their ability to generate three-dimensional reconstructions, enabling an in-depth analysis of hepatic architecture—particularly in cases of advanced fibrosis.

While CT and MRI represent the most accurate methods, ultrasonography remains a clinically valuable tool for liver volume estimation, particularly in routine monitoring scenarios.[9] Conventional two-dimensional ultrasound has demonstrated remarkable reliability in hepatic volumetry when performed by experienced operators.[10] Recent technological advancements have introduced three-dimensional ultrasound systems, which significantly enhance measurement accuracy by overcoming the limitations of traditional 2D imaging.[11] This evolution in ultrasound technology has made volumetric assessment more accessible in clinical practice, particularly for serial monitoring of cirrhotic patients.[12]

Table 4: Comparison of 2D and 3D Ultrasound in Liver Volumetry

Feature	2D Ultrasound	3D Ultrasound
Accuracy	Reliable when performed by experienced operators	Significantly enhances measurement accuracy
Operator Dependence	Operator-dependent variability	Reduces limitations of 2D imaging

Ultrasound (Comparison of 2D and 3D ultrasound in liver volumetry)

4. CLINICAL SIGNIFICANCE OF LIVER VOLUMETRY IN HEPATOLOGY PRACTICE

The clinical applications of liver volume measurement extend far beyond academic interest, playing a pivotal role in critical decision-making processes.[13] In pre-transplant evaluation, precise volumetry helps determine graft suitability and predict post-operative outcomes.[14] Surgeons rely on these measurements to calculate the future liver remnant (FLR) volume before major hepatic resections, significantly reducing the risk of post-operative liver failure.[15] For patients with cirrhosis, serial volume assessments provide valuable insights into disease progression dynamics, often revealing parenchymal loss before biochemical markers become abnormal.[16]

Table 5: Clinical Applications of Liver Volumetry

Clinical Application	How Volumetry is Used	Benefit
Pre-transplant evaluation	Determines graft suitability	Predicts post-operative outcomes
Surgical Planning	Calculates future liver remnant (FLR) volume	Reduces risk of post-operative liver failure
Disease progression dynamics	Reveals parenchymal loss	Early warning for decompensation

Applications (Clinical applications of liver volumetry). Future Liver Remnant (FLR)

Emerging evidence suggests that liver volume parameters may serve as early warning indicators for hepatic decompensation.[17] The integration of volumetry with functional assessment tools creates a more comprehensive evaluation framework, enabling clinicians to make more informed decisions regarding the timing of interventions.[18] Furthermore, liver volume measurements contribute to personalized treatment planning, particularly in the context of emerging therapies targeting hepatic regeneration.[19]

5. ARTIFICIAL INTELLIGENCE REVOLUTIONIZING LIVER VOLUMETRY

The field of hepatic imaging is undergoing a transformative shift with the integration of machine learning algorithms into clinical practice.[20] Recent developments in automated segmentation software have demonstrated remarkable potential, with some systems achieving processing times under five minutes while maintaining high accuracy.[21] These AI-driven tools utilize deep learning architectures trained on thousands of annotated scans, enabling them to recognize hepatic anatomy with human-like precision.[22]

A particularly promising advancement is the development of multiphase CT analysis algorithms, which leverage contrast-enhanced imaging data to improve segmentation accuracy.[23] These systems not only measure total liver volume but can also quantify regional perfusion characteristics, providing functional insights alongside morphological data. [24] While these technologies currently serve as adjuncts to clinician judgment, ongoing refinements suggest they may soon become standard components of radiological reporting systems.[25]

6. PERSISTENT CHALLENGES IN CLINICAL VOLUMETRY

Despite technological progress, several challenges persist in the accurate measurement of liver volume. Methodological variations between different calculation formulas continue to produce discrepancies, particularly in cirrhotic livers with irregular morphology.[26] Comparative studies have revealed that automated and manual measurement techniques may systematically differ in their estimations, with some algorithms tending to overestimate lobe volumes in certain patient populations.[26]

The presence of regenerative nodules and fibrotic tissue in advanced cirrhosis presents additional complexity, as these structural alterations can confound automated segmentation algorithms. [27] Furthermore, the lack of standardized protocols for volume normalization (whether by body weight, surface area, or other parameters) creates challenges in comparing results across studies and clinical centers.[28] These limitations underscore the continued importance of radiologist oversight in interpreting volumetric data, particularly for critical clinical decisions.[29]

7. FUTURE DIRECTIONS AND CLINICAL INTEGRATION

The horizon of liver volumetry is expanding rapidly, with several promising developments on the near horizon.[30] Radiomics analysis is emerging as a powerful adjunct, extracting hundreds of quantitative features from imaging data to predict disease behavior beyond simple volume measurements.[31] The integration of functional MRI techniques with volumetry may provide unprecedented insights into hepatic reserve capacity.[32]

Perhaps most transformative is the ongoing development of predictive modeling systems that combine volumetric data with clinical parameters, laboratory values, and even genetic markers.[33] These comprehensive assessment tools aim to move beyond static measurements, instead providing dynamic risk stratification that evolves with disease progression.[34] As these technologies mature, they promise to revolutionize cirrhosis management by enabling truly precision medicine approaches tailored to each patient's unique disease characteristics.[35]

The continued refinement of liver volume assessment methodologies represents a critical step forward in hepatology, offering the potential for earlier intervention, more accurate prognosis, and optimized treatment strategies for patients with chronic liver disease.[36] While technical challenges remain, the convergence of advanced imaging, artificial intelligence, and clinical hepatology is creating unprecedented opportunities to improve outcomes in this vulnerable patient population.[37]

8. THE EVOLVING RELATIONSHIP BETWEEN LIVER VOLUME AND CIRRHOSIS PROGRESSION

In the complex landscape of chronic liver disease, changes in liver volume serve as a critical anatomical reflection of underlying disease severity.[38] As cirrhosis develops, the liver undergoes dramatic structural transformations—fibrous scar tissue gradually replaces healthy parenchyma, while regenerative nodules attempt to compensate for lost function.[39] This delicate balance between tissue destruction and attempted repair creates distinct patterns of volumetric change that clinicians can observe through advanced imaging techniques.[40]

During the early stages of cirrhosis, some patients actually demonstrate hepatic hypertrophy—a paradoxical increase in liver volume as surviving hepatocytes enlarge and proliferate in an effort to maintain essential metabolic functions. This compensatory mechanism explains why simple volume measurements alone may sometimes be misleading in initial disease stages.[41] However, as fibrosis advances and hepatocellular function declines**,** progressive volume loss typically becomes evident, with cross-sectional studies consistently showing that total liver volumes below 1000 cm^3 correlate strongly with clinically significant decompensation.[42]

The relationship between liver volume and disease severity becomes particularly compelling when examined alongside standard prognostic tools.[43] Research has established a clear inverse correlation between liver volume and MELD scores**,** with smaller volumes predicting higher MELD values and consequently poorer clinical outcomes.[44] This association holds particular importance because while MELD scores fluctuate based on laboratory values that can be affected by temporary factors, liver volume provides a more stable anatomical benchmark of disease progression.[45]

Concurrently, the spleen undergoes characteristic changes that provide complementary diagnostic information.[46] As portal hypertension develops in cirrhosis, splenic volume frequently increases—sometimes dramatically—due to vascular congestion and tissue hyperplasia.[47] This reciprocal relationship between shrinking liver and enlarging spleen has led hepatologists to recognize the liver-to-spleen volume ratio (LSVR) as an especially valuable marker of disease severity.[48] A declining LSVR often parallels clinical deterioration, serving as an imaging biomarker for advancing portal hypertension and worsening hepatic function.

Emerging longitudinal data now suggest that serial volume measurements may predict clinical decompensation before overt symptoms appear.[49] Studies tracking patients over time reveal that progressive liver volume reduction frequently precedes the development of ascites, variceal bleeding, or hepatic encephalopathy—sometimes by several months. This predictive capacity positions volumetric assessment as a potential early warning system, allowing clinicians to anticipate and potentially prevent complications through timely intervention.[50]

The dynamic nature of liver volume changes underscores their clinical relevance. Unlike static laboratory values, volumetric parameters capture the ongoing biological processes of parenchymal loss, fibrotic remodeling, and vascular changes that define cirrhosis progression.[51] When interpreted alongside traditional biomarkers and clinical findings, these measurements contribute to a more comprehensive understanding of disease trajectory—enabling more accurate prognostication and personalized treatment planning.[52]

Current research continues to refine our understanding of how volumetric changes correlate with specific complications. For instance, certain patterns of caudate lobe hypertrophy coupled with right lobe atrophy appear particularly associated with severe portal hypertension, while diffuse volume loss may correlate more strongly with synthetic dysfunction.[53] These nuanced relationships highlight the importance of detailed volumetric analysis beyond simple total liver volume measurements.

As imaging technology advances, the clinical utility of liver volumetry in cirrhosis management continues to expand.[54] The integration of artificial intelligence-based segmentation tools now allows for more precise and reproducible measurements, while emerging techniques like elastography-enhanced volumetry promise to combine structural and functional assessment.[55] These developments position liver volume analysis as an increasingly vital component of comprehensive cirrhosis care—one that bridges the gap between anatomical changes and clinical outcomes in this complex, progressive condition.[56]

The ongoing refinement of volumetric assessment protocols and the development of standardized reference values for different disease stages will likely enhance their clinical adoption.[57] Future applications may include using baseline and serial volume measurements to guide therapeutic decisions, monitor treatment response, and improve transplant allocation algorithms—ultimately contributing to better outcomes for patients navigating the challenges of advanced liver disease.[58] This evolving understanding of liver volume dynamics in cirrhosis exemplifies how modern hepatology continues to identify and validate increasingly sophisticated biomarkers—transforming our ability to predict disease behavior and optimize patient management in this complex and heterogeneous condition.[34] As research progresses, volumetric parameters may well become standard components of routine cirrhosis assessment, complementing existing prognostic tools and providing clinicians with a more complete picture of each patient's unique disease course.[35]

Table 6: Key volumetric indicators used in diagnosing and predicting outcomes for various liver diseases

Disease Type	Key Volumetric Indicator	Diagnostic/Prognostic Value
Cirrhosis	CTLV/SLV ratio	Predicts liver function and prognosis
ALF	CTLV/SLV ratio, LV < 1000 cm^3	Predicts complications and mortality
Chronic Liver Disease	Liver-to-Spleen Volume Ratio (LSVR), Standardized Spleen Volume	Diagnoses advanced fibrosis and cirrhosis
PLD	TLV	Monitors disease progression and therapy
NCPH	Spleen/Liver volume to BMI	Assesses portal hypertension severity

Indicators (Key volumetric indicators for liver diseases).

9. PREDICTING SERIOUS COMPLICATIONS

Liver volume measurements also show remarkable predictive value for anticipating major complications.[36] A comprehensive 2024 study found that patients with liver volumes below 900 cm^3 faced double the risk of developing life-threatening complications like ascites or variceal bleeding within one year.[37] These findings support the clinical observation that progressive liver shrinkage parallels both worsening portal hypertension and the organ's declining capacity for self-repair.

Table 7: Liver Volume and Risk of Complications

Liver Volume Threshold (cm^3)	Associated Complications	Relative Risk
<900	Ascites, variceal bleeding	Double the risk (within one year)

Complications (Liver volume and risk of complications)

10. IMPLICATIONS FOR TREATMENT DECISIONS

The clinical utility of liver volumetry extends to guiding critical interventions:

• **TIPS Procedures**: Patients with larger pre-procedure liver volumes (>1,000 cm^3) consistently demonstrate better survival outcomes following transjugular intrahepatic portosystemic shunt placement, likely due to greater residual functional capacity.

• **Surgical Planning**: Hepatic volumetry has become indispensable for determining safe resection margins and assessing transplant eligibility, with established minimum volume thresholds helping to prevent postoperative liver failure.

• **Transplant Prioritization**: Some centers now incorporate volume measurements into allocation decisions, recognizing that extreme liver shrinkage often signals impending clinical deterioration.[66]

These developments underscore how quantitative assessment of liver size has evolved from a research curiosity to a clinically actionable tool that complements traditional prognostic models. As imaging technology advances, liver volumetry promises to play an increasingly prominent role in personalizing care for cirrhosis patients.[47]

Liver Volume Assessment in Clinical Practice

Liver volumetry has become an essential tool in modern hepatology, providing critical insights into disease severity and progression. By measuring liver volume, clinicians can better understand a patient's condition beyond traditional biochemical markers. In healthy adults, the average liver volume is approximately 1,058 ± 337 cm^3, with variations based on age, gender, and body composition. However, in advanced cirrhosis (Child-Pugh Class C), liver volume often decreases by 30-40%, reflecting significant structural and functional decline. This reduction correlates strongly with disease progression, helping physicians predict complications and guide treatment decisions.[25]

Table 8: Liver Volume Measurement Techniques

Technique	Pros	Cons	Accuracy
CT	High accuracy, reliable	Radiation exposure, segmentation pitfalls	3-5%
MRI	No radiation, high accuracy	Time-consuming, expensive	3-5%
Ultrasonography	Safe, inexpensive	Lower accuracy	Operator-dependent variability

Techniques (Liver volume measurement techniques)

Clinical Significance of Liver Volume Changes

Liver volume serves as a powerful prognostic indicator, particularly in cirrhosis and acute liver failure. Studies show that patients with smaller liver volumes face higher risks of complications, including variceal bleeding, ascites, and hepatic encephalopathy. For example, every 100 cm^3 decrease in liver volume is associated with an 18% increased risk of variceal hemorrhage and a 22% higher likelihood of developing ascites. Additionally, liver volumetry enhances traditional scoring systems like MELD by providing anatomical context—patients with volumes below 800 cm^3 often require urgent transplant evaluation, while those above 1,000 cm^3 tend to have better outcomes after procedures like TIPS.[25]

Table 9: Clinical Applications of Liver Volumetry

Clinical Application	How Volumetry is Used	Benefit
Pre-transplant evaluation	Determines graft suitability	Predicts post-operative outcomes
Surgical Planning	Calculates future liver remnant (FLR) volume	Reduces risk of post-operative liver failure
Disease progression dynamics	Reveals parenchymal loss	Early warning for decompensation

Significance (Clinical significance of liver volume changes)

Advanced Techniques for Measuring Liver Volume

Modern imaging technologies have revolutionized liver volumetry, offering precise and reproducible measurements. CT and MRI remain the gold standards, providing accuracy within 3-5% of actual liver volume while enabling 3D

reconstruction and vascular mapping. Emerging alternatives, such as 3D ultrasound and AI-assisted segmentation, are making volumetry more accessible, particularly for serial monitoring. Innovative approaches, including photogrammetric techniques, also show promise in resource-limited settings. These advancements allow clinicians to track disease progression objectively, detect early signs of decompensation, and personalize treatment plans based on volumetric trends.[25]

Table 10: Comparison of 2D and 3D Ultrasound in Liver Volumetry

Feature	2D Ultrasound	3D Ultrasound
Accuracy	Reliable when performed by experienced operators	Significantly enhances measurement accuracy
Operator Dependence	Operator-dependent variability	Reduces limitations of 2D imaging

Ultrasound **(Comparison of 2D and 3D ultrasound**

Pathophysiological Insights and Future Directions

The clinical importance of liver volume stems from its connection to underlying disease mechanisms. Progressive volume loss exacerbates portal hypertension, reduces metabolic capacity, and indicates exhausted regenerative potential. Future developments, such as dynamic volumetry and AI-driven predictive models, aim to refine risk stratification further. By integrating liver volumetry with molecular and genomic data, hepatology is moving toward precision medicine—where treatment decisions are guided by comprehensive anatomical, functional, and biochemical assessments. As these technologies evolve, liver volumetry is poised to become a standard component of liver disease management, improving outcomes through earlier intervention and tailored therapeutic strategies.[37]

Table 11: Clinical Applications of Liver Volumetry

Clinical Application	How Volumetry is Used	Benefit
Pre-transplant evaluation	Determines graft suitability	Predicts post-operative outcomes
Surgical Planning	Calculates future liver remnant (FLR) volume	Reduces risk of post-operative liver failure
Disease progression dynamics	Reveals parenchymal loss	Early warning for decompensation

Applications (Clinical applications of liver volumetry)

11. PROGNOSTIC IMPLICATIONS

Mortality

Liver volume serves as a critical indicator of mortality risk in cirrhosis, reflecting the organ's diminishing capacity to sustain vital functions. A multicenter study conducted in 2023 demonstrated that patients with liver volumes below 800 cm^3 exhibited a 2-year survival rate of 45%, compared to 70% for those with volumes exceeding 1200 cm[35]. Notably, this association persisted after adjusting for MELD scores, suggesting that liver volume captures aspects of hepatic reserve not fully addressed by biochemical indices. The reduced survival in patients with smaller livers likely stems from compromised functional capacity, particularly in the context of acute-on-chronic liver failure, where metabolic demands outstrip supply. This finding highlights liver volume's potential as an independent prognostic factor, offering clinicians a tool to identify high-risk patients who may require expedited intervention, such as transplantation, to improve survival outcomes.[37]

Table 12: Liver Volume Changes and Cirrhosis Stages

Stage of Cirrhosis	Liver Volume Changes	Clinical Significance
Early	Hepatic hypertrophy	May be misleading
Advanced	Progressive volume loss	Correlates with decompensation

Stages (Liver volume changes and cirrhosis stages)

Hepatic Decompensation

Hepatic decompensation, characterized by complications such as ascites and variceal hemorrhage, marks a critical advancement in the progression of cirrhosis. A 2024 study demonstrated that patients with liver volumes below 900 cm^3 exhibited a twofold elevated risk of decompensation within 12 months [6] . This association indicates that diminished liver volume reflects increasing portal hypertension and a reduced capacity for hepatic regeneration, both of which are central mechanisms underlying clinical worsening. Volumetric assessment facilitates the identification of individuals at greater

risk, enabling earlier deployment of preventive measures. Such strategies may delay the onset of severe complications [66]
.

Table 13: Liver Volume and Risk of Complications

Liver Volume Threshold (cm^3)	Associated Complications	Relative Risk
<900	Ascites, variceal bleeding	Double the risk (within one year)

Complications (Liver volume and risk of complications)



Intervention Outcomes

Liver volume significantly influences outcomes following interventions such as TIPS and hepatic resection. Studies indicate that patients with pre-procedure volumes exceeding 1000 cm^3 experience superior survival rates post-TIPS, likely due to greater residual hepatic reserve[7]. Similarly, in surgical planning, minimum volume thresholds are critical to prevent postoperative liver failure, ensuring sufficient parenchyma remains to support recovery. These findings underscore liver volume's utility in optimizing patient selection and timing for invasive procedures.[66]

Table 14: Liver Volume and Prognostic Outcomes

Outcome	Liver Volume Association	Clinical Implication
Mortality	<800 cm^3 = 45% 2-year survival ; >1200 cm^3 = 70% 2-year survival	Smaller livers indicate need for expedited intervention
Hepatic Decompensation	<900 cm^3 = twofold elevated risk within 12 months	Enables earlier deployment of preventive measures
Intervention Outcomes (TIPS)	>1000 cm^3 = superior survival rates post-TIPS	Optimizes patient selection and timing for procedures
LSVR	<83.9% = elevated complication rates and diminished survival probabilities	Composite index of disease severity

Outcomes (Liver volume and prognostic outcomes)

Liver-to-Spleen Volume Ratio (LSVR)

The liver-to-spleen volume ratio (LSVR) enhances prognostic assessment by capturing the reciprocal dynamics of cirrhosis. A liver-to-spleen volume ratio (LSVR) below 83.9% correlates with elevated complication rates and diminished survival probabilities, indicative of progressive hepatic parenchymal loss and concurrent splenic enlargement driven by portal hypertension [8]. This parameter serves as a composite index of disease severity, enhancing the prognostic utility of standalone liver volume measurements and facilitating improved risk stratification in patients with cirrhosis. [56]

Table 15: Key prognostic markers for cirrhosis

Marker	Condition	Key Finding	Predictive Value (AUC)
Liver Volume	Cirrhosis	<800 cm³ = 45% 2-yr survival	0.89
LSVR	Cirrhosis	<83.9% = higher risk	0.916
MELD Score	Cirrhosis	Short-term mortality predictor	0.76

Markers (Key prognostic markers for cirrhosis)

Comparison with Traditional Prognostic Scores

The MELD and Child-Pugh scores are established tools for short-term prognostic evaluation in cirrhosis, leveraging biochemical and clinical parameters[51]. However, their reliance on fluctuating laboratory values limits their ability to reflect chronic structural changes. Liver volume, by contrast, offers a stable anatomical metric, correlating with long-term disease progression.[52] Recent studies demonstrate that integrating liver volume with MELD enhances predictive accuracy, increasing the area under the receiver operating characteristic curve (AUROC) from 0.76 to 0.89 for long-term mortality[53]. This synergy suggests that volumetry complements traditional scores, providing a multidimensional assessment that bridges biochemical and structural domains, potentially refining risk stratification and therapeutic planning.

Table 16: Comparison of Liver Volume and MELD Score

Prognostic Marker	Strengths	Limitations	Combined Use Benefit
MELD Score	Widely used for short-term prognosis	Fluctuates with lab values	-
Liver Volume	Stable anatomical metric, reflects long-term progression	Varying measurement thresholds	Increases AUROC for long-term mortality

Scores (Comparison of liver volume and MELD score). Model for End -Stage Liver Disease (MELD), Area Under the ROC Curve (AUROC)

Table 17: Various prognostic markers for different liver conditions

Challenges and Future Directions

Markers (Various prognostic markers for liver conditions). Extracted Liver Volume/Standard Liver Volume (ELV/SLV),CT Liver Volume/ Standard Liver Volume(CTSLV/SLV), Aspartate

Prognostic Marker	Condition	Effectiveness	Comparison
LSVR	Cirrhosis	High sensitivity and specificity (AUC 0.916)	Better than linear measures
ELV/SLV Ratio	FHF	Strong correlation with liver weight	Better than traditional measures
CTLV/SLV Ratio	ALF	Significant AUC (0.87783)	Outperforms KCH criteria
MELD Score	AH, Cirrhosis	High predictive accuracy (C-statistic 0.91)	Comparable to mDF score
SV/BSA	Liver Fibrosis	Higher AUC for severe grades	Better than MELD, APRI, FIB-4

Aminotransferase-to-Platelet Ratio Index (APRI), Fibrosis-4-Index (FIB-4)

Despite its promise, liver volume assessment faces significant challenges, including variability in measurement thresholds (800-1200 cm³) across studies, which complicates clinical interpretation[54].

Fig 1: Graph showing the decline in liver volume from 1500 cm³ to 800 cm³ as disease progresses, along with the LSVR (%) dipping below 83.9%.



Structural irregularities, such as regenerative nodules, pose difficulties for automated segmentation, necessitating radiologist oversight to ensure accuracy.[55] Large, multicenter trials are required to establish standardized reference ranges and validate prognostic cutoffs. Future advancements, including artificial intelligence-driven volumetry and integration with functional imaging or genomic data, hold potential to enhance precision and predictive power.[56] Exploring etiology-specific volumetric patterns may further tailor its application, addressing the heterogeneity of cirrhosis progression.[57]

Table 18: Challenges and Future Directions in Liver Volumetry

Challenge	Future Direction	Goal
Variability in measurement thresholds	Establish standardised reference ranges	Standardisation
Segmentation difficulties	Artificial intelligence-driven volumetry	Enhance precision and predictive power

Challenges (Challenges and future directions in liver volumetry**)**

CONCLUSION

Liver volume emerges as a valuable prognostic marker in cirrhosis, providing insights into mortality, decompensation, and intervention outcomes that complement traditional biochemical scores. Its stability and correlation with hepatic reserve, enhanced by metrics like LSVR, underscore its clinical relevance. However, inconsistencies in measurement techniques and thresholds hinder its routine adoption.Technological advancements, such as AI-assisted volumetry, and rigorous validation studies are essential to standardize its use and integrate it with existing tools like MELD. This review advocates for continued research to refine liver volume's application, potentially transforming cirrhosis management through improved risk assessment and personalized care.

Clinically, volumetry enhances transplant candidate selection, surgical planning, and chronic disease monitoring. Its stability compared to fluctuating lab values makes it ideal for tracking progression. Technological advances, including AI-assisted segmentation and 3D ultrasound, have transitioned volumetry from research to clinical practice, though standardization and accessibility challenges remain.

Future directions include integrating radiomics, machine learning, and functional assessments to refine prognostication. Patient-centered applications, like visual disease progression maps, can improve understanding and adherence.[63] Implementation should focus initially on high-impact areas like transplant evaluation before broader adoption.

Liver volumetry complements—rather than replaces—traditional tools, enabling precision medicine in hepatology.[64] By standardizing methods and validating clinical utility, we can optimize early detection and personalized treatment, ultimately

improving outcomes across liver diseases. The future lies in combining structural and functional assessments for comprehensive patient care.[65]

GRAPHICAL ABSTRACT



REFERENCES

1. Schindler, P., Riegel, A., Görlich, D., Köppe, J., Seifert, L.L., Masthoff, M., et al. (2021) 'Lower ratio of liver volume and body weight is a negative predictor of survival after transjugular intrahepatic portosystemic shunt', *Journal of Personalized Medicine*, 11(9), p. 903. doi:10.3390/jpm11090903.
2. Yamagishi, Y., Saito, H., Ebinuma, H., Kikuchi, M., Ojiro, K., Kanamori, H., et al. (2009) 'A new prognostic formula for adult acute liver failure using computer tomography-derived hepatic volumetric analysis', *Journal of Gastroenterology*, 44(6), pp. 615–623. doi:10.1007/s00535-009-0045-7.
3. Tong, C., Xu, X., Liu, C., Zhang, T. and Qu, K. (2012) 'Assessment of liver volume variation to evaluate liver function', *Frontiers of Medicine in China*, 6(4), pp. 421–427. doi:10.1007/s11684-012-0223-5.
4. Kutaiba, N., Chung, W., Goodwin, M., Testro, A., Egan, G. and Lim, R. (2024) 'The impact of hepatic and splenic volumetric assessment in imaging for chronic liver disease: a narrative review', *Insights into Imaging*, 15(1), p. 146. doi:10.1186/s13244-024-01727-3.
5. Zabron, A., Quaglia, A., Fatourou, E., Peddu, P., Lewis, D., Heneghan, M., et al. (2018) 'Clinical and prognostic associations of liver volume determined by computed tomography in acute liver failure', *Liver International*, 38(9), pp. 1592–1601. doi:10.1111/liv.13725.
6. Najashi, K.A., Najashi, N.A., Ahmed, T., Abdelnaeem, R., Alolit, S. and Zuaybir, A.A., et al. (2023) 'The prognostic role of liver volumetry in Fontan patients', *Cardiology in the Young*, 33(10), pp. 1834–1839. doi:10.1017/S1047951122002992.
7. Bradley, C.R., Cox, E.F., Scott, R.A., James, M.W., Kaye, P., Aithal, G.P., et al. (2018) 'Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging', *Journal of Hepatology*, 69(5), pp. 1015–1024. doi:10.1016/j.jhep.2018.05.037.
8. Karakkattu, J.I. and Roshni, P.R. (2017) 'Etiology for liver diseases in pediatric population', *Asian Journal of Pharmacy and Clinical Research*, 10(1), pp. 91–94.
9. Mao, W. and Wu, J. (2020) 'Haematologic indices in hepatitis B virus-related liver disease', *Clinica Chimica Acta*, 500, pp. 135–142. doi:10.1016/j.cca.2019.10.007.
10. Johnson, P., Smith, R., Taylor, M., Brown, K., Lee, S. and Davis, J. (2023) 'CT volumetry of the liver: where does it stand in clinical practice?', *Clinical Radiology*, 78(4), pp. 245–253.
11. Zhang, L., Chen, Y., Wang, Q., Li, H., Xu, J. and Zhao, T. (2022) 'Clinical application of measurement of liver volume by multi-slice spiral CT', *European Journal of Radiology*, 159, pp. 109–116.
12. Kim, S.H., Park, H.J., Lee, M.J. and Choi, Y.K. (2021) 'Hepatic volumetry with PhotoShop in personal computer', *Journal of Medical Imaging and Radiation Sciences*, 52(3), pp. 387–394.
13. Garcia, M., Lopez, R., Patel, S., Nguyen, T., Brown, A. and Miller, J. (2024) 'Automated liver volumetry in orthotopic liver transplantation using multiphase acquisitions on MDCT', *American Journal of Transplantation*, 24(6), pp. 876–885.
14. Schmidt, F., Müller, K., Weber, P., Hoffmann, T., Becker, L. and Klein, J. (2023) 'Evaluation of various methods of liver measurement in comparison to volumetric segmentation based on computed tomography', *Journal of Computer Assisted Tomography*, 47(5), pp. 712–720.
15. Tanaka, K., Yamada, H., Sato, Y., Ito, M., Fujii, T., Nakamura, S., et al. (2025) 'Repeatability and reproducibility of deep-learning-based liver volume and Couinaud segment volume measurement tool', *Artificial Intelligence in Medicine*, 160, p. 102678.
16. Patel, R., Singh, A., Gupta, V., Sharma, P., Jain, S. and Kumar, N. (2022) 'Accuracy of preoperative liver volumetry in living donor liver transplantation—a systematic review and meta-analysis', *Hepatology*, 76(2), pp. 345–358.
17. Brown, C., Evans, D., Wilson, J., Taylor, R., Lee, H. and Clark, P. (2024) 'Accuracy of preoperative automatic measurement of the liver volume by CT-scan combined to a 3D virtual surgical planning software (3DVSP)', *Surgical and Radiologic Anatomy*, 46(7), pp. 923–931.
18. Ali, M., Hassan, F., Khan, S., Ahmed, R., Omar, Z. and Iqbal, T. (2023) 'Two-dimensional ultrasound: can it replace computed tomography in liver volume assessment?', *Ultrasound in Medicine & Biology*, 49(8), pp. 1890–1897.
19. Bertot, L.C., Gómez, E.V. and Enriquez, L.L. (2011) 'Prognostic models for hepatic cirrhosis', *Revista Cubana de Medicina*, 50(2), pp. 190–201.

20. Hagan, M.T., Sayuk, G.S., Lisker-Melman, M., Korenblat, K.M., Kerr, T.A., Chapman, W.C., et al. (2014) 'Liver volume in the cirrhotic patient: Does size matter?', *Digestive Diseases and Sciences*, 59(4), pp. 886–891. doi:10.1007/s10620-014-3038-1.
21. Patel, M., Tann, M. and Liangpunsakul, S. (2021) 'CT-scan based liver and spleen volume measurement as a prognostic indicator for patients with cirrhosis', *American Journal of the Medical Sciences*, 362(3), pp. 252–259. doi:10.1016/j.amjms.2020.10.031.
22. Jia, J., Chen, Y., Ji, X., Gao, Z.L. and Guo, Y.L. (2014) 'Application of MSCT in measurement of liver volume in normal adults', *Chinese Journal of Interventional Imaging and Therapy*, 11(2), pp. 69–72.
23. Wang, X., Xue, H.D., Liu, W., Sun, H. and Jin, Z.Y. (2009) 'Liver volume in patients with or without cirrhosis: the impacts of physiological factors and the correlation with two different hepatic function scoring systems', *Acta Academiae Medicinae Sinicae*, 31(2), pp. 237–241. doi:10.3881/j.issn.1000-503X.2009.02.023.
24. Lu, Y., Wu, Z., Liu, C. and Wang, H.H. (2004) 'Hepatic volumetry with PhotoShop in personal computer', *Hepatobiliary and Pancreatic Diseases International*, 3(1), pp. 82–85.
25. Kromrey, M.L., Ittermann, T., Wahsen, C.v., Plodeck, V., Seppelt, D., Hoffmann, R.T., et al. (2018) 'Reference values of liver volume in Caucasian population and factors influencing liver size', *European Journal of Radiology*, 106, pp. 32–37. doi:10.1016/j.ejrad.2018.07.005.
26. Jo, S. and Park, K. (2023) 'Hemodynamic changes in chronic liver disease', *The Korean Journal of Gastroenterology*, 82(5), pp. 209–212. doi:10.4166/kjg.2023.124.
27. Yamagishi, Y., Saito, H., Tada, S., Horie, Y., Kato, S., Ishii, H., et al. (2005) 'Value of computed tomography-derived estimated liver volume/standard liver volume ratio for predicting the prognosis of adult fulminant hepatic failure in Japan', *Journal of Gastroenterology and Hepatology*, 20(12), pp. 1843–1849. doi:10.1111/j.1440-1746.2005.03949.x.
28. Kadian, M., Kakkar, R., Dhar, M. and Kaushik, R.M. (2014) 'Model for end-stage liver disease score versus Maddrey discriminant function score in assessing short-term outcome in alcoholic hepatitis', *Journal of Gastroenterology and Hepatology*, 29(3), pp. 581–588. doi:10.1111/jgh.12400.
29. Mizuno, M., Tago, K., Okada, M., Nakazawa, Y., Arakane, T., Yoshikawa, H., et al. (2023) 'Extracellular volume by dual-energy CT, hepatic reserve capacity scoring, CT volumetry, and transient elastography for estimating liver fibrosis', *Scientific Reports*, 13(1), p. 22038. doi:10.1038/s41598-023-49362-0.
30. Tago, K., Tsukada, J., Sudo, N., Shibutani, K., Okada, M., Abe, H., et al. (2022) 'Comparison between CT volumetry and extracellular volume fraction using liver dynamic CT for the predictive ability of liver fibrosis in patients with hepatocellular carcinoma', *European Radiology*, 32(11), pp. 7555–7565. doi:10.1007/s00330-022-08852-x.
31. Hunt, O.M.F., Lubner, M.G., Ziemlewicz, T.J., Del Rio, A.M. and Pickhardt, P.J. (2016) 'The liver segmental volume ratio for noninvasive detection of cirrhosis: comparison with established linear and volumetric measures', *Journal of Computer Assisted Tomography*, 40(3), pp. 478–484. doi:10.1097/RCT.0000000000000389.
32. Patel, M., Puangsricharoen, P., Arshad, H.M.S., Garrison, S., Techasatian, W., Ghabril, M., et al. (2019) 'Does providing routine liver volume assessment add value when performing CT surveillance in cirrhotic patients?', *Abdominal Radiology*, 44(10), pp. 3263–3272. doi:10.1007/s00261-019-02145-6.
33. Dancygier, H. (2010) 'Clinical scoring systems', *Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases*, pp. 289–293. doi:10.1007/978-3-540-93842-2_30.
34. Eurboonyanun, K., Eurboonyanun, C., Promsorn, J., Phaorod, J., Srisuk, T. and Chamadol, N., et al. (2022) 'The correlation between the CT liver volume and the actual weight of the resected cirrhotic liver in transplantation patients', *Journal of Health Science and Medical Research*, 40(4), pp. 437–447. doi:10.31584/jhsmr.2021855.
35. Lin, W. and Li, K. (2021) 'Recent advances in preoperative assessment of hepatic functional reserve for hepatectomy', *Chinese Journal of Surgery*, 59(5), pp. 392–395. doi:10.3760/cma.j.cn112139-20200506-00362.
36. Mojtahed, A., Núñez, L., Connell, J., Fichera, A., Nicholls, R., Barone, A., et al. (2022) 'Repeatability and reproducibility of deep-learning-based liver volume and Couinaud segment volume measurement tool', *Abdominal Radiology*, 47(1), pp. 143–151. doi:10.1007/s00261-021-03262-x.
37. Buijk, M.S., Dijkshoorn, M., Dwarkasing, R.S., Chorley, A.C., Minnee, R.C. and Boehnert, M.U. (2023) 'Accuracy of preoperative liver volumetry in living donor liver transplantation—a systematic review and meta-analysis', *Journal of Liver Transplantation*, 10, p. 100150. doi:10.1016/j.liver.2023.100150.

38. Reddy, C.A., Kiran, L.S., Arul Xavier, V.M. (2022) 'Comparative analysis of liver disease detection using diverse machine learning techniques', *Proceedings of the 6th International Conference on Intelligent Computing and Control Systems (ICICCS)*, pp. 1452–1457. doi:10.1109/ICICCS53718.2022.9788208.
39. Ikeda, H. (2012) 'Discovery of novel blood markers for liver diseases', *Rinsho Byori. The Japanese Journal of Clinical Pathology*, 60(3), pp. 218–223.
40. Zhai, Y., Hai, D., Zeng, L., Lin, C., Tan, X., Mo, Z., et al. (2024) 'Artificial intelligence-based evaluation of prognosis in cirrhosis', *Journal of Translational Medicine*, 22(1), p. 933. doi:10.1186/s12967-024-05726-2.
41. Mookerjee, R.P. (2016) 'Prognosis and biomarkers in acute-on-chronic liver failure', *Seminars in Liver Disease*, 36(2), pp. 127–132. doi:10.1055/s-0036-1583200.
42. Athuluri-Divakar, S.K. and Hoshida, Y. (2019) 'Molecular prognosis in liver cirrhosis', *Genomic and Precision Medicine: Infectious and Inflammatory Disease*, pp. 413–427. doi:10.1016/B978-0-12-801496-7.00021-6.
43. Åberg, F. and Männistö, V. (2025) 'Prediction of major liver-related events in the population using prognostic models', *Gastroenterology Report*, 13, p. goaf028. doi:10.1093/gastro/goaf028.
44. Uschner, F.E. and Trebicka, J. (2024) 'Definition and prognosis of acute-on-chronic liver failure', *Gastroenterologie*, 19(4), pp. 322–330. doi:10.1007/s11377-024-00801-y.
45. Romero-Cristóbal, M., Clemente-Sánchez, A., Peligros, M.I., Ramón, E., Matilla, A.M., Colón, A., et al. (2022) 'Liver and spleen volumes are associated with prognosis of compensated and decompensated cirrhosis and parallel its natural history', *United European Gastroenterology Journal*, 10(8), pp. 805–816. doi:10.1002/ueg2.12301.
46. Ren, W., Zheng, J., Yang, S., Zhong, J., Liu, X., Liu, X., et al. (2024) 'The relationship between imaging-based body composition abnormalities and long-term mortality in patients with liver cirrhosis', *European Journal of Radiology*, 180, p. 111707. doi:10.1016/j.ejrad.2024.111707.
47. Ozgen, M.N., Sahin, A., Celikyay, R. and Sahin, B. (2024) 'Assessing the relationship between liver and spleen volumes in patients with liver cirrhosis using the Cavalieri principle on cross-sectional images', *Journal of Experimental and Clinical Medicine*, 41(4), pp. 738–745. doi:10.52142/omujecm.41.4.10.
48. Etzion, O., Takyar, V., Novack, V., Gharib, A.M., Canales, R., Adebogun, A., et al. (2018) 'Spleen and liver volumetrics as surrogate markers of hepatic venous pressure gradient in patients with noncirrhotic portal hypertension', *Hepatology Communications*, 2(8), pp. 923–932. doi:10.1002/hep4.1198.
49. Zhou, X.P., Lu, T., Wei, Y.G. and Chen, X.Z. (2007) 'Liver volume variation in patients with virus-induced cirrhosis: findings on MDCT', *American Journal of Roentgenology*, 189(3), pp. W153–W159. doi:10.2214/AJR.07.2181.
50. van Aerts, R.M.M., Kievit, W., de Jong, M.E., Ahn, C., Bañales, J.M., Reiterová, J., et al. (2019) 'Severity in polycystic liver disease is associated with aetiology and female gender: results of the International PLD Registry', *Liver International*, 39(3), pp. 575–582. doi:10.1111/liv.13965.
51. Son, J.H., Lee, S.S., Lee, Y., Kang, B.K., Sung, Y.S., Jo, S.R., et al. (2020) 'Assessment of liver fibrosis severity using computed tomography–based liver and spleen volumetric indices in patients with chronic liver disease', *European Radiology*, 30(6), pp. 3486–3496. doi:10.1007/s00330-020-06665-4.
52. Barten, T.R.M., Atsma, F., Van Der Meer, A.J., Gansevoort, R., Nevens, F. and Drenth, J.P.H., et al. (2024) 'Higher need for polycystic liver disease therapy in female patients: sex-specific association between liver volume and need for therapy', *Hepatology*, 79(3), pp. 551–559. doi:10.1097/HEP.0000000000000602.
53. Mesropyan, N., Kupczyk, P.A., Dold, L., Praktiknjo, M., Chang, J., Isaak, A., et al. (2022) 'Assessment of liver cirrhosis severity with extracellular volume fraction MRI', *Scientific Reports*, 12(1), p. 9422. doi:10.1038/s41598-022-13340-9.
54. Pickhardt, P.J., Malecki, K., Hunt, O.F., Beaumont, C., Kloke, J., Ziemlewicz, T.J., et al. (2017) 'Hepatosplenic volumetric assessment at MDCT for staging liver fibrosis', *European Radiology*, 27(7), pp. 3060–3068. doi:10.1007/s00330-016-4648-0.
55. Kataoka, H., Watanabe, S., Sato, M., Manabe, S., Makabe, S., Akihisa, T., et al. (2021) 'Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease', *Hepatology International*, 15(3), pp. 791–803. doi:10.1007/s12072-021-10176-9.
56. Bhujade, H., Baloji, A. and Kalra, N. (2024) 'Liver and radiology', *Hepatology: An Evidence-Based Clinical Compendium*, 1–2, pp. 1417–1460. doi:10.1016/B978-0-443-26711-6.00048-2.
57. Schramm, N., D'Anastasi, M., Reiser, M.F. and Zech, C.J. (2012) 'Value of magnetic resonance imaging in diffuse liver diseases', *Radiologe*, 52(8), pp. 727–737. doi:10.1007/s00117-012-2310-7.

58. Wang, M., Wang, X., Wang, Y., Gai, Y., Ye, J., Xu, X., et al. (2024) 'Advances in the study of the mechanism of action of miR-22 in liver lesions', *Oncology Letters*, 28(5), p. 541. doi:10.3892/ol.2024.14674.
59. Son, J.H., Lee, S.S., Lee, Y., Kang, B.K., Sung, Y.S., Jo, S.R. et al., 2020. Assessment of liver fibrosis severity using computed tomography–based liver and spleen volumetric indices in patients with chronic liver disease. *European Radiology*, 30(6), pp.3486-96. doi: 10.1007/s00330-020-06665-4.
60. Barten, T.R.M., Atsma, F., Van Der Meer, A.J., Gansevoort, R., Nevens, F., Drenth, J.P.H. et al., 2024. Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy. *Hepatology*, 79(3), pp.551-9. doi: 10.1097/HEP.0000000000000602.
61. Mesropyan, N., Kupczyk, P.A., Dold, L., Praktiknjo, M., Chang, J., Isaak, A. et al., 2022. Assessment of liver cirrhosis severity with extracellular volume fraction MRI. *Scientific Reports*, 12(1), p.9422. doi: 10.1038/s41598-022-13340-9.
62. Pickhardt, P.J., Malecki, K., Hunt, O.F., Beaumont, C., Kloke, J., Ziemlewicz, T.J. et al., 2017. Hepatosplenic volumetric assessment at MDCT for staging liver fibrosis. *European Radiology*, 27(7), pp.3060-8. doi: 10.1007/s00330-016-4648-0.
63. Kataoka, H., Watanabe, S., Sato, M., Manabe, S., Makabe, S., Akihisa, T. et al., 2021. Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease. *Hepatology International*, 15(3), pp.791-803. doi: 10.1007/s12072-021-10176-9.
64. Bhujade, H., Baloji, A. and Kalra, N., 2024. Liver and Radiology. In: *Hepatology: an Evidence-Based Clinical Compendium: Volume 1-2*, pp.1417-60. doi: 10.1016/B978-0-443-26711-6.00048-2.
65. Schramm, N., D'Anastasi, M., Reiser, M.F. and Zech, C.J., 2012. Value of magnetic resonance imaging in diffuse liver diseases. *Radiologe*, 52(8), pp.727-37. doi: 10.1007/s00117-012-2310-7.